NYSE · GLS
Healthcare · Biotechnology
$0.16
Up+$0.00 (+0.00%)
Updated Sep 18, 2026, 11:59 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
GLS does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning GLS.
GLS research
Company profile and research snapshot.
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 20, 2022 | Citigroup | Neutral | — |
No generated briefing is available yet.
globenewswire.com · Nov 12, 2025
GLS drives e-commerce delivery innovation with smart services and an expanding Out of Home network. In partnership with Quadient, it adds open, carrier-agnostic lockers to its Italian offering.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLS.
No results
No recent SID articles mention GLS.
